Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Eli Lilly builds $1.5 billion stockpile of weight-loss pill ahead of FDA decision
Eli Lilly builds $1.5 billion stockpile of weight-loss pill ahead of FDA decision
FILE PHOTO: A drone view shows the Eli Lilly logo on one of the company’s offices in San Diego, California, U.S., November 21, 2025. REUTERS/Mike Blake/File Photo · Reuters
Reuters
Fri, February 13, 2026 at 5:27 AM GMT+9 1 min read
In this article:
LLY
+3.35%
Feb 12 (Reuters) - Eli Lilly had $1.5 billion worth of pre-launch inventory of its experimental oral weight-loss drug, a filing showed on Thursday, ahead of an expected decision by the U.S. Food and Drug Administration in April.
Last year, the company had said it had nearly $550 million in pre-launch inventory for the pill, orforglipron.
Lilly has previously said it would have plenty of supply to launch the much-anticipated weight-loss pill in several countries nearly simultaneously if the pill wins U.S. approval.
Danish rival Novo Nordisk launched its once-daily weight-loss pill in the U.S. earlier this month, with prescriptions hitting more than 26,000 in the second full week after launch, IQVIA data shared by an analyst showed.
Orforglipron won a fast-track review voucher from the FDA that could cut review times to as little as one to two months, from the typical 10 to 12 months for most new medicines.
Most drugmakers include such inventories, or assets, in their financial statements to show how much drug product has been manufactured right before approval.
(Reporting by Sneha S K in Bengaluru; Editing by Sriraj Kalluvila)
Terms and Privacy Policy
Privacy Dashboard
More Info